Hunt S, Jennifer P. Hellwig
Nursing for Women’s Health, Volume 22, Issue 1, 2018, Page 12, ISSN 1751-4851, https://doi.org/10.1016/S1751-4851(18)30022-9.
2018-02-01
https://www.sciencedirect.com/science/article/pii/S1751485118300229
The U.S. Food and Drug Administration (FDA) approved the first drug in the United States with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor; Otsuka America Pharmaceutical, Inc., Rockville, MD) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for treatment of schizophrenia, for acute treatment of manic and mixed episodes associated with bipolar I disorder, and for use as an add-on treatment for depression in adults. Abilify MyCite is the first digital medicine system to be cleared by the FDA and will be launched with a limited rollout. Consumers can track daily medication intake using the companion mobile app; health care providers can be given access to the information through a Web-based portal.